Wednesday, December 19, 2018
News
NEWS HOME
»
PRN INDIA
ZAXINE® (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)1,2
  SocialTwist Tell-a-Friend  
   

BSE: 500257    |    NSE: LUPIN    |    REUTERS: LUPIN.BO    |    BLOOMBERG: LPCIN

MONTREAL, Dec. 6, 2018 /PRNewswire/ --  Lupin Pharma Canada is pleased to announce the approval from Health Canada for ZAXINE ® 550 mg (rifaximin) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. ZAXINE ® for IBS-D is being launched in December of 2018 under a strategic licensing agreement with Salix Pharmaceuticals, Ltd., one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. The agreement grants Lupin exclusive rights to promote, distribute and market ZAXINE ®  in Canada. This is in addition to ZAXINE ®'s previously approved indication for the reduction in risk of overt hepatic encephalopathy (HE) in adults.1  

Canada has one of the highest rates of IBS worldwide, affecting 13-20% of the population.2, 3 Of those who do suffer from IBS, about one third have IBS with diarrhea as the primary symptom. Although the exact cause of IBS-D is not known, scientists believe that the microbiota in the gastrointestinal (GI) tract plays an important role in the development of the symptoms associated with IBS-D, such as abdominal pain, bloating, and diarrhea.1

Speaking on the occasion, Dr. Sofia Mumtaz, President - Pipeline Management & Legal, Lupin said, "We are delighted to receive the approval from Health Canada for ZAXINE ® (rifaximin, 550 mg tablets) for the treatment of IBS-D. With this new indication approved, the medical fraternity and patients will now have access to an effective medication against one of the most rampantly prevailing issues of IBS-D."

"There is an unmet treatment need for those who have irritable bowel syndrome with diarrhea, so this is great news for those still grappling to manage their digestive symptoms", said Gail Attara, Chief Executive Officer of the Gastrointestinal Society, a patient group known for its popular website, www.badgut.org.

The safety and efficacy of ZAXINE ® 550 mg three times daily for 2 weeks were demonstrated in 3 Phase-III placebo-controlled trials. After treatment, significantly more ZAXINE ®-treated patients experienced self-reported relief of IBS symptoms.1 In addition, a significantly greater proportion of ZAXINE ®-treated patients reported relief of abdominal pain and improvement in stool consistency.1, 4

"In irritable bowel syndrome, it is not always easy to manage the symptoms effectively," said Dr. Guy Aumais, MD, CSPQ, FRCP (C), Gastroenterologist at Maisonneuve-Rosemont and Associate Professor, University of Montreal. He further added, "ZAXINE ® is a short-term, two-week therapy for IBS-D, which will act on symptoms such as diarrhea, bloating and abdominal pain, with lasting relief. With this indication, we now have an interesting new option in the management of IBS-D."

"An alteration in host-microbiota interactions is a factor in the expression of subsets of IBS patients. ZAXINE ® has been shown to improve symptoms in diarrhea predominant IBS-D and its action is likely mediated through attenuation of host microbiota interactions and subsequent symptom generation. This is an important new treatment option for IBS-D patients", said Dr. Stephen Collins MBBS, FRCP (UK), FRCPC, Professor, Department of Medicine at McMaster University.  

ABOUT ZAXINE ® (RIFAXIMIN)

ZAXINE ® (rifaximin)'s primary mode of action reduces the bacterial load and bacterial products that can negatively affect the patient, alleviating the most common symptoms of IBS-D including bloating, abdominal pain and diarrhea.1  

As an antibacterial agent that acts locally on the microflora of the gut thereby altering the gut microbiota, ZAXINE ® represents an important new therapeutic option in the treatment of IBS-D.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization (30th September 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th June 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3rd largest Indian pharmaceutical company by global revenues (30th June 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31st March 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal.

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

 

ZAXINE ® (rifaximin)  is manufactured by:

Salix Pharmaceuticals, Inc.

400 Somerset Corporate Boulevard

Bridgewater, NJ 08807

USA

In Canada, ZAXINE ® (rifaximin) is distributed exclusively by:

Lupin Pharma Canada Ltd

1001 Bd. De Maisonneuve East

Suite 304, Montréal, Québec H2L 4P9

Canada

 

References:

  1. ZAXINE ® Product Monograph. Salix Pharmaceuticals, Inc., November 30, 2018.
  2. http://cdhf.ca/en/disorders/irritable-bowel-syndrome-ibs/section/resources
  3. https://www.badgut.org/information-centre/a-z-digestive-topics/ibs/
  4. Pimentel M, Lembo A, Chey WD et al. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. N Engl J Med 2011; 364:22-32.

For queries please contact: Isabel Longval, Marketing Director – Lupin Pharma Canada Ltd, Email: Isabellongval@lupin.com; Pooja Thakran, VP – Global Corporate Communications, Email: poojathakran@lupin.com, Ph: +91-22-66402531 / 8291013225


More News by PR Newswire India

Sprinklr's Social Media Management Platform, Experience Cloud, Acclaimed by Frost & Sullivan for Helping Brands Improve Customer Engagement

Polycom Acclaimed by Frost & Sullivan for its Next-generation Enterprise Communication Endpoints

Cision Names Valerie Lopez Vice President of Global Diversity, Equity and Inclusion

CleverTap and SonyLIV partner to improve user experience with video push notifications

Coinsquare launches into the European Union

LimeTray, a Restaurant Management Company, Completes 5 Years

Sun Life Financial to Acquire Majority Stake in Bentall GreenOak

Bentall Kennedy and GreenOak Real Estate announce merger to form Bentall GreenOak, global real estate investment platform

Mumbai Jewellery & Gem Fair to Showcase Statement Pieces From Prime Indian Jewellers

Essence takes on integrated media duties for Airtel

JA Solar Supplies Modules for the First 3MW Bifacial Mono PERC Double Glass Solar Project in Brazil

Metasys(R) 10.0 redefines modern building management

Lipofilling, Expanded Stem Cells Are a Valuable Alternative to Breast Implants

Locus Chain to Launch a Digital Asset Exchange Platform in Dubai

Wood Adhesives Manufacturers Focus their Growth Strategy on Furniture, Building and Construction Industries

The Commonwealth Of The Bahamas New Visa Waiver Policy for Indian Nationals Holding Canadian, Schengen, USA and UK Visas

Big Data and IoT Advancements Drive Growth Opportunities for Prognostics in Commercial Vehicles

Supermicro Report Highlights Environmental Impact of Today's Cloud-Scale Data Centers

HTC Partners With China Mobile To Expand Its 5G Vision Globally

HUAWEI P20 Pro Honoured at the Prestigious News18 Tech and Auto Awards for Best Camera Phone of the Year

Intermarché maps its own-brand organic products using SGS Transparency-One

Xevo Recognized by Frost & Sullivan for its Groundbreaking Xevo Market Automotive Commerce and Services Platform

TATA Projects Builds Prayagraj Airport Terminal in 11 Months

New Report Explores Digital Travel Commerce and Payments Needs in Latin America & Caribbean

ThroughPut Inc Announces the Formation of Executive Advisory Board, Welcomes New Members

27th Mega Eye Camp Held at Dera Sacha Sauda

Mumbai to get its First Professionally Managed Self-redevelopment Project by Wedevelopment

ARLANXEO's Keltan(R) KSA opens flagship online Customer Self-Service Platform

Western Digital Hosts 'Data Innovation Bazaar' in Association With 'Startup India' and 'Invest India'

GIIS Chinchwad Amongst 0.1% Schools in India to Receive Cambridge Affiliation

Munters Wins Three Large Air Treatment Orders in China

Datamatics Recognized as the Best Cognitive Technology Provider by Computer Society of India, Mumbai

Indiannica Learning Organizes English Language Training (ELT) Workshop and Product Launch

Nishchae Suri to Join the Global Management Executive Team at EdCast

'Marketing Success Formula' a New Book by Rajesh Srinivasan (an IIM-L Alumnus) Reveals Four Proven Steps for Business Growth

HopOn India to Participate in Comic-Con 2018

Lenovo and Intel's Much-anticipated Legion of Champions III 2019 is Here and Raring to Go

UST Global Awarded 'Top Employers in the APAC for 2019' by the Top Employers Institute

Singapore Post eCommerce Division Recognised at the 2018 Asia eCommerce Awards

Empire State Building And Interscope Records, Along With iHeartMedia, Promise A "White Christmas" With Annual Holiday Music-To-Light Show Featuring OneRepublic

Shoclef Presents Live Shopping in the Global Marketplace

Ski Season Opens at Lotte Arai Resort on December 15

AWE 2019 releases new theme: Falling in love with AI - Smart Life

New Report Shows Rapid Damage to Milk Nutrients by Light

Artificial Intelligence Is Propelling the Pharmaceutical Industry by Enabling Smart Drug Discovery Solutions

Few Months Into the Launch, NowPaaS is Already a Success; Has Serviced More Than 100+ Manufacturers

Cityzenith's Smart World Pro™ Digital Twin Software Platform Selected for New Capital City in India

Frost & Sullivan Applauds VMware for Global Software-Defined Wide Area Networking (SD-WAN) Market Leadership

The Rise of Industrial IoT Drives the Adoption of Predictive Inspection Models in Non-destructive Testing

After New Delhi, Indus Towers now Deploys 50 Intelligent Poles in Vadodara Under Government's Smart City Mission

Systech Releases Expanded Cloud Platform to Secure Global Supply Chains

KC Valley: MEIL’s another Glory

Top IT Jobs in Demand in India, Revealed by Simplilearn Study

Maxim India Achieves the Distinction of India's First Progressive 3D Mainstream Magazine Cover - Courtesy OnePlus

Microland Wins Best Practice Award at the NHRD TecHeaRt 2018

Kerala Tourism Launches International Children's Online Painting Competition 2018 in Memory of Edmund Thomas Clint

Fosun's Protechting Program wins UNGC's China Network award for its Sustainable Development in China

Cross-border Data Flows Fundamental for AI Growth in India

Affle Wins Big at MOBEXX Awards 2018

BioNet reports on persistence of antibody responses of recombinant pertussis vaccines in the Lancet Infectious Diseases

Datamatics to Demerge and Separately List its Subsidiary Lumina Datamatics

Dunya Labs Brings EOS Blockchain to India With Catalyst

Exclusive Launch: Karan Wahi X Spoyl Collection

Join in the 2018 world-leading Tea Fair with the gracious invitation extended by Huajuchen

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
AIADMK MPs protest inside Parliament pre...
SC seeks Centre's reply on suggestions t...
Fate of 14 trapped in Meghalaya mine rem...
Bulandshahr violence: Slain youth's fami...
ML subject most subscribed by Indians on...
1984 anti-Sikh riots: Yashpal Singh bail...
More...    
 
 Top Stories
Atletico first team players, coach ... 
Lok Sabha passes Bill that prohibit... 
3 injured in stabbing at London hea... 
Pope rejects seasonal consumerism... 
100 days not enough to plan for no-... 
S. Africa issues arrest warrant aga... 
India reiterates support for peace ... 
Bulandshahr violence 'political con...